PT  - JOURNAL ARTICLE
AU  - Tadler, Scott C.
AU  - Jones, Keith G.
AU  - Lybbert, Carter
AU  - Huang, Jason C.
AU  - Jawish, Rana
AU  - Solzbacher, Daniela
AU  - Kendrick, E. Jeremy
AU  - Pierson, Matthew D.
AU  - Weischedel, Kamile
AU  - Rana, Noreen
AU  - Jacobs, Rebecca
AU  - Vonesh, Lily C.
AU  - Feldman, Daniel A.
AU  - Larson, Claire
AU  - Hoffman, Nathan
AU  - Jessop, Jacob E.
AU  - Larson, Adam L.
AU  - Taylor, Norman E.
AU  - Odell, David H.
AU  - Kuck, Kai
AU  - Mickey, Brian J.
TI  - Propofol for treatment resistant depression: A randomized controlled trial
AID  - 10.1101/2023.09.12.23294678
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.09.12.23294678
4099  - http://medrxiv.org/content/early/2023/09/15/2023.09.12.23294678.short
4100  - http://medrxiv.org/content/early/2023/09/15/2023.09.12.23294678.full
AB  - Background Anesthetic agents including ketamine and nitrous oxide have shown antidepressant properties when appropriately dosed. Our recent open-label trial of propofol, an intravenous anesthetic known to elicit transient positive mood effects, suggested that it may also produce robust and durable antidepressant effects when administered at a high dose that elicits an electroencephalographic (EEG) burst-suppression state. Here we report findings from a randomized controlled trial (NCT03684447) that compared two doses of propofol. We hypothesized greater improvement with a high dose that evoked burst suppression versus a low dose that did not.Methods Participants with moderate-to-severe, treatment-resistant depression were randomized to a series of 6 treatments at low versus high dose (n=12 per group). Propofol infusions were guided by real-time processed frontal EEG to achieve predetermined pharmacodynamic criteria. The primary and secondary depression outcome measures were the 24-item Hamilton Depression Rating Scale (HDRS-24) and the Patient Health Questionnaire (PHQ-9), respectively. Secondary scales measured suicidal ideation, anxiety, functional impairment, and quality of life.Results Treatments were well tolerated and blinding procedures were effective. The mean [95%-CI] change in HDRS-24 score was −5.3 [−10.3, −0.2] for the low-dose group and −9.3 [−12.9, −5.6] for the high-dose group (17% versus 33% reduction). The between-group effect size (standardized mean difference) was −0.56 [−1.39, 0.28]. The group difference was not statistically significant (p=0.24, linear model). The mean change in PHQ-9 score was −2.0 [−3.9, −0.1] for the low dose and −4.8 [−7.7, −2.0] for the high dose. The between-group effect size was −0.73 [−1.59, 0.14] (p=0.09). Secondary outcomes favored the high dose (effect sizes magnitudes 0.1 - 0.9) but did not generally reach statistical significance (p>0.05).Conclusions The medium-sized effects observed between doses in this small, controlled, clinical trial suggest that propofol may have dose-dependent antidepressant effects. The findings also provide guidance for subsequent trials. A larger sample size and additional treatments in series are likely to enhance the ability to detect dose-dependent effects. Future work is warranted to investigate potential antidepressant mechanisms and dose optimization.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT03684447Funding StatementSupported by a gift from Peter Huntsman, the Huntsman Mental Health Institute, a Research Instrumentation Fund grant from the University of Utah Vice President for Research, and the University of Utah Clinical & Translational Science Institute (UL1TR002538)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research was approved by the University of Utah Institutional Review Board.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors